48th week of 2011 patent applcation highlights part 52 |
Patent application number | Title | Published |
20110294743 | METASTASIS-SPECIFIC PEPTIDES AND THEIR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes. | 2011-12-01 |
20110294744 | CYCLOSPORIN EMULSIONS - Disclosed herein is a composition comprising cyclosporin A at a concentration between about 0.001% (w/v) and about 1.0% (w/v), a plant oil at a concentration between about 0.01% (w/v) and about 10% (w/v), and macrogol 15 hydroxystearate at a concentration between about 0.01% (w/v) and about 10% (w/v). | 2011-12-01 |
20110294745 | SOLUTIONS OF LIPOPHILIC SUBSTANCES, ESPECIALLY MEDICINAL SOLUTIONS - The present invention relates to a solution containing at least one water-miscible biocompatible solvent and a lipophilic substance dissolved therein, wherein upon contact with aqueous body fluid the dissolved lipophilic substance is precipitated out of the solution in the form of nanoparticles and a nanosuspension is formed. | 2011-12-01 |
20110294746 | PHARMACEUTICAL MICROEMULSION FOR PREVENTING SUPRAMOLECULAR AGGREGATION OF AMPHIPHILIC MOLECULES - The present invention refers to a microemulsion formulation suitable for preventing assembly of amphiphilic drug molecules which may cause hypersensitivity reactions and other unwanted side effects. | 2011-12-01 |
20110294747 | PEGYLATED MUTATED CLOSTRIDIUM BOTULINUM TOXIN - The invention relates to a modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain resides in that it comprises (i) an extension of the chain on its N-terminus which has the structure —(C) | 2011-12-01 |
20110294748 | Insulin-like growth factor 1 receptor binding peptides - The present invention relates to insulin-like growth factor 1 receptor binding peptides, polynucleotides encoding them, and methods of making and using the foregoing. | 2011-12-01 |
20110294749 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE - A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. | 2011-12-01 |
20110294750 | SURFACE STERILISATION BY MISTING WITH A BIOFLAVANOID SOLUTION - There is described a method of sterilizing surfaces using flavonoids, for example mixtures containing inter alia naringin and neohesperidin, by misting. | 2011-12-01 |
20110294751 | HIGH DOSAGE DORAMECTIN FORMULATION - Veterinary compositions which provide a high-dose of doramectin or a high-dose veterinary combination composition which comprises doramectin and one or more other antiparasitic agents is disclosed. The compositions provide both antiparasitic efficacy and a significantly reduced withhold time. | 2011-12-01 |
20110294752 | TRITERPENE COMPOSITIONS AND METHODS FOR USE THEREOF - The invention provides novel saponin mixtures and compounds which are isolated from the species | 2011-12-01 |
20110294753 | Means and methods for counteracting muscle disorders - The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival. | 2011-12-01 |
20110294754 | NOVEL PHARMACEUTICAL COMPOUNDS - Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders. | 2011-12-01 |
20110294755 | BINDING OF GALECTIN-3 BY LOW MOLECULAR WEIGHT PECTIN - Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials. | 2011-12-01 |
20110294756 | GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of heterocyclic compounds of Group A or Group, as defined herein, as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions. | 2011-12-01 |
20110294757 | POLAR LIPID MIXTURES, THEIR PREPARATION AND USES - Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidyl-inositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM>PC>PE>PS>PI or SM=PC>PE>PS>PI. Processes for the preparation of said mixtures and uses thereof are also described herein. | 2011-12-01 |
20110294758 | NOVEL ACTIVATORS OF GLUCOKINASE - The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same. | 2011-12-01 |
20110294759 | Once daily formulations of tetracyclines - Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. | 2011-12-01 |
20110294760 | Compositions and Methods for Preventing Sternal Wound Infections - The invention generally relates to compositions and methods for preventing sternal wound infections, such as mediastinitis. In certain embodiments, the invention provides an antimicrobial composition including at least one bioresorbable polymer, such as a tyrosine-derived polyesteramide, and at least one antimicrobial agent, in which the composition is adapted to be topically applied to an esophageal perforation in a subject or a median sternotomy incision site in the subject, and in which the at least one antimicrobial agent is present in an amount effective to inhibit development of mediastinitis in the subject. | 2011-12-01 |
20110294761 | STEM CELL CULTURES - The present invention relates compounds for stabilizing cells and methods of their use. | 2011-12-01 |
20110294762 | GLYCERYL AND GLYCOL ACID COMPOUNDS - A composition comprising a glyceryl salicylate compound and/or a glycol salicylate compound. The compositions can be used to reduce the amount of moisture evaporated from skin, protect the skin from UV light, and treat aged or damaged skin. | 2011-12-01 |
20110294763 | TRANSDERMAL DELIVERY OF DICOLFENAC, CARBAMAZEPINE AND BENZYDAMINE - The invention discloses solutions of diclofenac, carbamazepine and benzydamine, at therapeutically desirable concentrations and the solutions stable for extended periods of time at room temperature. | 2011-12-01 |
20110294764 | 2-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 2011-12-01 |
20110294765 | Procedure for obtaining an aqueous dispersion of alcohols and acids from jojoba oil, processes for obtaining self-emulsified jojoba oil, aqueous dispersions and emulsions of jojoba oil in the same and pharmaceutical or cosmetic compositions comprising the same - Processes for obtaining aqueous dispersions comprising alcohols and acids obtained by hydrolysis of jojoba oil. Hydrolyzed jojoba oil products are treated by a process comprising neutralization of jojoba fatty acids with aliphatic organic amines dissolved in a co-solvent followed by the dispersion of both the neutralized fatty acids together with jojoba alcohols in an aqueous medium. The products obtained, generically named hydrolyzed jojoba oil (HJO), promote transdermal absorption and are useful vehicles for carrying a wide range of pharmaceutical and cosmetic compositions, including pharmaceutical and cosmetic compositions comprising either lipophilic or hydrophilic active principles. The HJO can also be used to produce a semisolid, self-emulsified jojoba oil (SEJO), obtained by emulsifying the HJO in jojoba oil. | 2011-12-01 |
20110294766 | 16 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use - The present invention provides compounds of formula (I) wherein R | 2011-12-01 |
20110294767 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS - Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions. | 2011-12-01 |
20110294768 | Ophthalmic Suspension for Ocular Use - A gatifloxacin and prednisolone topical ophthalmic pharmaceutical compositions for prevention and treatment of ophthalmic bacterial infections and inflammatory conditions associated with pre-surgical and/or post surgical ocular surgeries. | 2011-12-01 |
20110294769 | NITROOXY DERIVATIVES OF GLUCOCORTICOIDS - The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability. | 2011-12-01 |
20110294770 | METHOD FOR PRODUCING PHARMACEUTICAL DRUG PARTICLES OF SMALL PARTICLE SIZE - Pharmaceutical drug particles of small particle size are produced by combining a solvent-non-solvent precipitate with an in-situ spray drying process. A pharmaceutical drug is dispersed in a water-miscible solvent, in particular ethanol, and heated in an infeed line under pressure to above the boiling point of the solvent until the drug dissolves. This solution collides as a fine liquid jet with a fine water jet in a gas-permeated microreactor, and the fine mist so arising vaporises rapidly. The organic solvent vaporizes first, then the water. The water may contain surface modifiers. | 2011-12-01 |
20110294771 | TREATMENT OF MUSCULAR DYSTROPHY - The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided. | 2011-12-01 |
20110294772 | USE OF CYCLOSQUARAMIDE COMPOUNDS AS ANTI-TUMOUR AGENTS - Use of squaramide-based macrocylic compounds as kinase inhibitor agents and as anti-tumour agents. More specifically, said compounds are used to treat diseases such as cancer, diabetes, neurodegenerative diseases, HIV replication, etc. Furthermore, the present invention likewise relates to pharmaceutical compositions that contain said compounds | 2011-12-01 |
20110294773 | COSMETIC COMPOSITION AND HAIR WASH - To provide a cosmetic composition and a hair wash which are excellent in metal pyrithione salt persistence after washing with a washing liquid containing a surfactant, etc. | 2011-12-01 |
20110294774 | IDENTIFICATION AND APPLICATION OF ANTIBIOTIC SYNERGY - The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a β-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS. Further provided is a method of discovering synergists for antibiotics including: a) expressing in a cell an antisense nucleic acid against a nucleic acid encoding a gene product so as to reduce the activity or amount of the gene product in the cell, thereby producing a cell sensitized to an antibiotic; b) characterizing the sensitization of the cell to the antibiotic and selecting pairs of antibiotics and genes that result in antibiotic efficacy at one-fifth or less the concentration required in the absence of the antisense gene; c) screening for chemical compounds that inhibit the gene product corresponding to the selected synergistic gene; and d) selecting or creating chemical analogs that inhibit the gene product corresponding to the selected synergistic gene such that the inhibition occurs in the bacteria. | 2011-12-01 |
20110294775 | NOVEL COMPOUNDS - Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain and headache diseases. The following is exemplary: | 2011-12-01 |
20110294776 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases - This invention relates to novel compounds of formula (I). Formula (I) in which the variable groups are as defined in the specification and claims, to pharmaceutical compositions containing them, and to a method of treatment using them for treatment of cancer. | 2011-12-01 |
20110294777 | BETA-LACTAMASE INHIBITORS - Substituted bicyclic beta-lactams of Formula I: (I), are β-lactamase inhibitors, wherein a, X, R | 2011-12-01 |
20110294778 | HEPATITIS C INHIBITOR COMPOUNDS - Compounds of Formula (I) | 2011-12-01 |
20110294779 | NOVEL IMIDAZOPYRIDINES - The invention is concerned with novel imidazopyridine derivatives of formula (I) | 2011-12-01 |
20110294780 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS - The present invention relates to compounds of Formula (I), | 2011-12-01 |
20110294781 | PYRAZOLO-PYRIMIDINE COMPOUNDS - The present invention has searched for a variety of compounds which show IL-12/IL-23 production-inhibitory activities and herein provides a pharmaceutical composition and an agent for preventing or treating IL-12/IL-23 excess production-related diseases, which comprise the compound. | 2011-12-01 |
20110294782 | SMALL MOLECULE PAK INHIBITORS - The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering small molecule p21-activated kinase (PAK) inhibitors to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides specific small molecule PAK inhibitors and pharmaceutical compositions comprising small molecule PAK inhibitors. | 2011-12-01 |
20110294783 | Insecticidal Compositions Having Improved Effect - The present invention concerns boosting the activity of crop protection materials comprising inhibitors of fatty acid biosynthesis (for example phenyl-substituted cyclic ketoenols) through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium salts and/or phosphonium salts and penetrants, the corresponding materials, processes for preparing them, and their use in crop protection. | 2011-12-01 |
20110294784 | GAMMA SECRETASE MODULATORS - This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (Chemical formula should be inserted here as it appears on abstract in paper form). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I). | 2011-12-01 |
20110294785 | INFLUENZA A VIRUS INHIBITION - Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein. | 2011-12-01 |
20110294786 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 2011-12-01 |
20110294787 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES - The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use. | 2011-12-01 |
20110294788 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS - The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF. | 2011-12-01 |
20110294789 | COMPOUNDS FOR RHO KINASE INHIBITION AND FOR IMPROVING LEARNING AND MEMORY - The present invention provides a compound of Formula (I) and methods for improving memory, inhibiting rho kinase 1 or 2, inhibiting PIM kinase, or inhibiting IRAK1 kinase in a subject by administering a therapeutically effective amount of the compound. | 2011-12-01 |
20110294790 | BICYCLIC PYRAZOLE AND ISOXAZOLE DERIVATIVES AS ANTITUMOR AND ANTINEURODEGENERATIVE AGENTS - Bicyclic pyrazole and isoxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases mediated by HSP90 protein, like cancer and neurodegenerative disorders. | 2011-12-01 |
20110294791 | PIRENZEPINE AS AN AGENT IN CANCER TREATMENT - The present invention generally relates to the neuroprotective activity of condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine. These compounds are suitable as co-medicaments for the prevention and/or treatment of drug-induced neurotoxic effects in general and neurotoxic side effects during cancer treatments with cytostatic drugs such as platinum-derivatives, e.g. cis-, carbo- and oxaliplatin, taxanes, bleomycin, cyclophosphamide and vincristine etc. Further, these compounds have an intrinsic anti-cancer activity on their own due to PARP-1 inhibition, which prevents NADH depletion in oxidative metabolism of healthy cells thus preventing the shift to anoxygenic, glycolytic metabolism present in many types of tumour cells thus eliminating this crucial metabolic advantage favoring tumour growth. These results exploit the fact of differential PARP-1 expression between many cancer cells and healthy tissues. | 2011-12-01 |
20110294792 | PURINE DERIVATIVES AS KINASE INHIBITORS - The present invention provides kinase inhibitors of Formula I. | 2011-12-01 |
20110294793 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS - The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, compositions containing the compounds and methods of treating diseases using the compounds. | 2011-12-01 |
20110294794 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR - Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a therapeutically effective amount of a farnesyl transferase inhibitor, wherein the amount is effective to inhibit the farnesylation of a non-Ras FTase substrate involved in the autophagy pathway without substantially affecting the farnesylation of Ras or other oncology related substrates. Treatments in accordance with the present invention may also include an acetylcholinesterase inhibitor, an activator of neurotrophic receptors, an NMDA anatagonist, an amyloid deposit inhibitor, an antipsychotic agent, an antidepressant, an anxiolytic, or an antioxidant. | 2011-12-01 |
20110294795 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - Described are compositions and methods of making high purity diaminophenothiazinium compounds of the following formula | 2011-12-01 |
20110294796 | BENZOTRIAZINE INHIBITORS OF KINASES - The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases. | 2011-12-01 |
20110294797 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO - Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis. | 2011-12-01 |
20110294798 | IL-12 MODULATORY COMPOUNDS - The invention relates to cyclic hydrazone compounds, compositions including the cyclic hydrazone compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12. | 2011-12-01 |
20110294799 | Organic Compounds - The invention relates to compound of the formula I | 2011-12-01 |
20110294800 | HYPOGLYCEMIC DIHYDROPYRIDONES - The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods of treatment or prevention of diabetes or hyperglycemia in a patient, and of normalizing blood glucose levels in a subject, by administering an effective amount of a compound of formula I. | 2011-12-01 |
20110294801 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS - Macrocyclic derivative compounds that inhibit protein kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed kinase activity such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases. | 2011-12-01 |
20110294802 | PHARMACEUTICALLY ACCEPTABLE SALTS OF METHYL (3-{ [[3-(6- AMINO- 2-BUTOXY-8-OXO-7, 8-DIHYDRO-9H-PURIN-9-YL) PROPYL] (3- MORPHOLIN-4-YLPROPYL) AMINO] METHYL }PHENYL) ACETATE AND THEIR USE IN THERAPY - The present invention concerns hydrochloric acid, hydrobromic acid and maleic acid salts of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate, compositions comprising them and their use in therapy. | 2011-12-01 |
20110294803 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS - Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific inhibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling mechanism and genetic network associated with schizophrenia and with schizophrenia-associated risk variation in ErbB4. A risk pathway associated with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor CYT-1 and a specific PI3K enzyme, PIK3CD has been identified. | 2011-12-01 |
20110294804 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND - The invention provides a compound for the treatment or prophylaxis of pathology involving SNS, specifically diseases such as neuropathic pain, nociceptive pain, dysuria, multiple sclerosis and the like. The compound is represented by formula (1) or a pharmaceutically acceptable salt thereof wherein R | 2011-12-01 |
20110294805 | PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF - The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I | 2011-12-01 |
20110294806 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS - This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use. | 2011-12-01 |
20110294807 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE - Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula (I) | 2011-12-01 |
20110294808 | Indazole Compounds As CCR1 Receptor Antagonists - Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2011-12-01 |
20110294809 | TROPANE UREA DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS MODULATORS OF THE ACTIVITY OF 11BETAHSD1 - The invention relates to tropane urea derivatives of general formula (I) and to the application thereof as modulators of the activity of 11β-hydroxysteroid dehydrogenose type 1 (11βHSD1). | 2011-12-01 |
20110294810 | SUBSTITUTED (PYRIDYL)-AZINYLAMINE DERIVATIVES AS PLANT PROTECTION AGENTS - The present invention relates (pyridyl)-azinylamino derivatives of formula (I) wherein Q | 2011-12-01 |
20110294811 | ABT-263 CRYSTALLINE FORMS - ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2011-12-01 |
20110294812 | P38 MAP KINASE INHIBITORS - The invention relates to compounds of formula (I): | 2011-12-01 |
20110294813 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 - Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. | 2011-12-01 |
20110294814 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS - Disclosed are compounds of Formula (I) and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. | 2011-12-01 |
20110294815 | PROSTACYCLIN ANALOGS - This invention relates to novel prostacyclin analogs and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel prostacyclin analogs that are derivatives of treprostinil. This invention also provides compositions comprising a compound of this invention and a carrier and the use disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering analogues of prostacyclin, such as treprostinil. | 2011-12-01 |
20110294816 | PYRROLOTRIAZINE KINASE INHIBITORS - The present invention provides compounds of formula I | 2011-12-01 |
20110294817 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR - The invention related to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R | 2011-12-01 |
20110294818 | 1H-QUINAZOLINE-2,4-DIONES - The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) | 2011-12-01 |
20110294819 | Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein. | 2011-12-01 |
20110294820 | N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives - The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans. | 2011-12-01 |
20110294821 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 2011-12-01 |
20110294822 | Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof - The invention relates to a substituted phenylpiperazine aryl alkanol derivative represented by the following general formula and its salt and hydrate, | 2011-12-01 |
20110294823 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS - Tetrahydroindolone and aryl piperazine derivatives for use in treating post-traumatic stress disorder and acute stress disorder. | 2011-12-01 |
20110294824 | POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL)BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE HYDROCHLORIDE - The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation. | 2011-12-01 |
20110294825 | POLYMORPHIC FORMS OF 1-'4-(5-CYANOINDOL-3-YL)BUTYL-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE HYDROCHLORIDE - The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation. | 2011-12-01 |
20110294826 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS - Described herein are pyrrolo[2,3-d]pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing these compounds, and methods for their preparation. | 2011-12-01 |
20110294827 | IAP BINDING COMPOUNDS - IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K | 2011-12-01 |
20110294828 | PROCESS FOR PREPARING A POLYMORPH OF THE CHOLINE SALT OF A PYRIMIDIN-5-YL ACETIC ACID DERIVATIVE - Provided is a process for preparing a choline salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid. The process of the invention is useful for preparing the salt in purer forms of the salt. Also disclosed is a more pure form of the of choline salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid. | 2011-12-01 |
20110294829 | FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES - The present invention relates to hydroximoyl-heterocycle derivatives of formula (I) | 2011-12-01 |
20110294830 | NITROGEN-CONTAINING COMPOUNDS AND HARMFUL ORGANISM CONTROL AGENTS - The present invention provides a nitrogen-containing compound represented by formula (I | 2011-12-01 |
20110294831 | 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.- 1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT - The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions. | 2011-12-01 |
20110294832 | FUSED RING COMPOUND AND USE THEREOF - Provided is a novel compound represented by the following formula | 2011-12-01 |
20110294833 | Methods for Healthy Aging - Genome-wide association studies have been used to elucidate genes and/or pathways related to diseases; however, this methodology has yet to be used to understand the phenotype of healthy aging and/or healthspan in humans. | 2011-12-01 |
20110294834 | Alkyl-substituted pyrazolopyrimidines - The invention relates to novel alkyl-substituted pyrazolopyrimidines, process for their preparation, and the use thereof for producing medicaments for improving perception, concentration, learning and/or memory. | 2011-12-01 |
20110294835 | Muscarinic Agonists as Cognitive Enhancers - A method of treating a mental condition in a subject in need thereof, comprising: administering to a subject in need thereof an effective amount of compound CDD-102A. | 2011-12-01 |
20110294836 | ARYL GPR119 AGONISTS AND USES THEREOF - Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control. | 2011-12-01 |
20110294837 | Aurora Kinase Modulators and Methods of Use - The present invention relates to chemical compounds having a general formula I | 2011-12-01 |
20110294838 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE - The invention relates to sulfoximine-substituted anilino-pyrimidine derivatives of formula (I). | 2011-12-01 |
20110294839 | NOVEL POLYMORPHS OF LOPINAVIR - The present invention provides a novel cyclohexane solvate form of lopinavir, and a process for its preparation thereof. The present invention also provides a novel desolvated crystalline form of lopinavir, process for its preparation and to pharmaceutical composition containing it. Thus, for example, lopinavir cyclohexane solvate was heated at 100° C. for 10 hours to give lopinavir desolvated crystalline form H1. | 2011-12-01 |
20110294840 | HYDRAZIDE COMPOUND AND USE OF THE SAME IN PEST CONTROL - There is provided a hydrazide compound having a controlling effect on pests represented by the formula (1): wherein, G is a 5-membered heterocyclic group, M is an oxygen atom or a sulfur atom, Q | 2011-12-01 |
20110294841 | NOVEL STATIN PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF TREATMENT - The invention provides novel omega-3 oil formulations of one or more statins. These formulations are readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oils as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. The invention also provides novel salts of one or more statins. | 2011-12-01 |
20110294842 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN - This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R | 2011-12-01 |